Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
2024年10月15日 - 10:00PM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced a collaboration with
Flatiron Health, a leading health tech company dedicated to
expanding the possibilities of point of care solutions in oncology.
This collaboration allows physicians to order Myriad’s
MyRisk® Hereditary Cancer Test and view the results of the
test directly in Flatiron’s cloud-based Electronic Medical Record
(EMR) platform, OncoEMR®. MyRisk is the first hereditary cancer
test to be incorporated into Flatiron’s OncoEMR.
The integration allows 4,200 providers at over 800
community-based cancer care locations across the U.S. in Flatiron’s
network to conveniently order, receive, and review MyRisk testing
results directly through their daily OncoEMR system. By creating a
streamlined, end-to-end workflow for germline testing in OncoEMR,
clinicians have access to the results they need at point-of-care,
facilitating personalized treatment decisions for patients while
reducing administrative burdens and improving turnaround times for
results.
“Our collaboration with Flatiron integrates MyRisk testing with
practicing clinicians’ current workflows, potentially enhancing
access to and usability of germline testing for more personalized
patient care,” said George Daneker Jr, MD, President and Chief
Clinical Officer of Oncology, Myriad Genetics. “By making germline
testing interoperable with OncoEMR, we aim to simplify the ordering
experience for clinicians in Flatiron’s extensive network and
provide important health information that may help improve patient
care and outcomes. We look forward to expanding the availability of
our other genomic testing solutions onto the OncoEMR platform in
the future, addressing the needs of even more patients.”
“As we continue to advance personalized medicine, the importance
of germline testing at the point of care is critical to improving
patient outcomes,” said Stephen Speicher, MD, Senior Medical
Director, Head of Clinical Oncology and Patient Safety at Flatiron
Health. “By giving physicians the ability to order Myriad’s MyRisk
Hereditary Cancer Test and to view the results directly within
OncoEMR, we're offering clinicians a seamless way to access the
information they need to practice precision medicine, facilitating
better patient outcomes, more time with patients, and a better care
experience for physicians and their patients.”
The integration is available now to all OncoEMR users.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor Statement This press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements relating to how the company’s collaboration with
Flatiron may facilitate personalized treatment decisions for
patients while reducing administrative burdens and improving
turnaround times for results and how by making germline testing
interoperable with OncoEMR, the company aims to simplify the
ordering experience for clinicians in Flatiron’s extensive network
and provide important health information that may help improve
patient care and outcomes. These “forward-looking statements” are
management’s expectations of future events as of the date hereof
and are subject to known and unknown risks and uncertainties that
could cause actual results, conditions, and events to differ
materially and adversely from those anticipated. Such factors
include those risks described in the company’s filings with the
U.S. Securities and Exchange Commission, including the company’s
Annual Report on Form 10-K filed on February 28, 2024, as well as
any updates to those risk factors filed from time to time in the
company’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. Myriad is not under any obligation, and it expressly disclaims
any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise
except as required by law.
About Flatiron HealthFlatiron Health is a
healthtech company expanding the possibilities for point of care
solutions in oncology and using data for good to power smarter care
for every person with cancer. Through machine learning and AI,
real-world evidence, and breakthroughs in clinical trials, we
continue to transform patients’ real-life experiences into
knowledge and create a more modern, connected oncology ecosystem.
Flatiron Health is an independent affiliate of the Roche Group.
Myriad Genetics Investor Contact Matt
Scalo (801) 584-3532 IR@myriad.com
Myriad Genetics Media Contact Glenn
Farrell (385) 318-3718 PR@myriad.com
Flatiron Health Media ContactNina
Toorpress@flatiron.com
Myriad Genetics (NASDAQ:MYGN)
過去 株価チャート
から 9 2024 まで 10 2024
Myriad Genetics (NASDAQ:MYGN)
過去 株価チャート
から 10 2023 まで 10 2024